Combination Treatment With Curcumin and Quercetin of Adenomas in Familial Adenomatous Polyposis

MARCIA CRUZ–CORREA,* † DANIEL A. SHOSKES,§ PATRICIA SANCHEZ,* RHONGUA ZHAO,* LINDA M. HYLIND,† STEVEN D. WEXNER,‖ and FRANCIS M. GIARDIELLO‡ †¶,§
Departments of *Medicine, ‡Kidney Transplant, and §Surgery, Cleveland Clinic, Weston, Florida; †Department of Medicine, ‡Oncology Center, and ¶Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Background & Aims: Familial adenomatous polyposis (FAP) is an autosomal-dominant disorder characterized by the development of hundreds of colorectal adenomas and eventual colorectal cancer. Regression of adenomas in this syndrome occurs with the administration of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors, but these compounds can have considerable side effects. We evaluated the efficacy of the combination of diet-derived nonprescription supplements curcumin and quercetin to regress adenomas in patients with FAP.

Methods: Five FAP patients with prior colectomy (4 with retained rectum and 1 with an ileal anal pouch) received curcumin 480 mg and quercetin 20 mg orally 3 times a day. The number and size of polyps were assessed at baseline and after therapy. The Wilcoxon signed-rank test was used to determine differences in the number and size of polyps. Treatment side effects and medication compliance were also evaluated.

Results: All 5 patients had a decreased polyp number and size from baseline after a mean of 6 months of treatment with curcumin and quercetin. The mean percent decrease in the number and size of polyps from baseline was 60.4% (P < .05) and 50.9% (P < .05), respectively. Minimal adverse side effects and no laboratory abnormalities were noted.

Conclusions: The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity. Randomized controlled trials are needed to validate these findings.
The combination of curcumin and quercetin to regress intestinal adenomas in 5 patients with FAP.

**Methods**

**Patients**

Five white FAP patients with previous colectomy, 4 with ileorectal anastomosis and 1 with ileoanal pull through with ileal anal pouch, were enrolled in the study. Patients were recruited from the Cleveland Clinic in Weston, Florida. Inclusion criteria were patients with FAP who had undergone colectomy with retained rectum or ileal pouch who had 5 or more adenomas. Exclusion criteria included the use of nonsteroidal anti-inflammatory drugs for more than 1 week over the prior 3 months. The study was approved by the Cleveland Clinic Institutional Review Board, and informed consent was obtained from the patients.

**Study Design**

Participants were examined by flexible sigmoidoscopy using an Olympus flexible sigmoidoscope (Olympus, Melville, NY) before administration (0 mo) and at 3-month intervals (range, 3–9 mo) after the initiation of treatment with curcumin and quercetin. The number and size of polyps were evaluated at each visit. Also, at each endoscopy examination, 2 polyps were sampled for histology with care taken not to remove the polyps. No effort was made to clear the rectum of polyps by polypectomy or excisional biopsy procedure. One observer (M.C.C.) performed all assessments. The endoscopist counted the total number of polyps in the entire circumference of the rectum from the ileorectal anastomosis to the anal verge or in the ileal pouch. The diameter of the largest polyp was measured in millimeters, with a graduated scale passed through the sigmoidoscopic biopsy channel.

Each patient received curcumin 480 mg and quercetin 20 mg orally 3 times a day using Oxy-Q tablets (Farr Laboratories, Santa Clarita, CA). Also, patients were instructed not to take nonsteroidal anti-inflammatory drugs during this trial. Patient compliance with drug administration was assessed by tablet count and monthly telephone contact. Safety was monitored by monthly telephone interviews and at follow-up visits. In addition, complete blood count was obtained and levels of glucose, blood urea nitrogen, serum creatinine, serum electrolytes, and bilirubin were measured at each visit. Adverse events were graded in accordance with the Common Toxicity Criteria of the National Cancer Institute.12

**Statistical Analysis**

The outcome variables analyzed were the number and size of polyps at the end of treatment. In addition, the percentage change from baseline in the number and size of polyps was evaluated. Mean, standard deviation, median, and range were reported where appropriate. Hypothesis testing was performed by Wilcoxon signed-rank test (pair analysis) using STATA 8.0 statistical software (STATA Corporation, College Station, TX).

**Results**

**Clinical Effect**

Table 1 shows the demographic characteristics of the study patients. Four of the patients had colectomy with ileorectal anastomosis and retained rectum and 1 had proctocolectomy with an ileoanal pouch. All patients had 5 or more polyps at baseline. Patients were treated for a mean of 6 months of therapy (range, 3–9 mo). Patient 1 was found to be noncompliant with scheduled treatment doses between 3 and 6 months of therapy. After re-instruction of the patient concerning the medication schedule, she was continued on therapy for an additional 3 months (months 6–9). Patient 5 was lost to follow-up evaluation after 3 months of treatment.

Figure 1 shows the polyp number for the 5 patients over the course of treatment with curcumin and quercetin. A decrease in polyp number from baseline was noted in 4 of 5 patients at 3 months and 4 of 4 patients at 6 months of treatment. Of note, polyp number in patient 1 paralleled the course of treatment with curcumin and quercetin. One patient concerning the medication schedule, she was continued on therapy for an additional 3 months (months 6–9). Patient 5 was lost to follow-up evaluation after 3 months of treatment.

The mean decrease in polyp number from baseline with treatment was 60.4% (P = .043) (Table 2). The mean decrease in polyp size from baseline with treatment was 50.9% (P = .039).

**Adverse Effects and Compliance**

Few adverse side effects were reported with combination treatment with curcumin and quercetin. One patient reported a grade 1 episode of nausea and sour taste that occurred for 1–2 hours after pill ingestion and abated after 3 days without recurrence. One patient had a grade 1 self-limited episode of loose stools for 5 days during the study period. Abnormalities in laboratory study results were

### Table 1. Demographic Characteristics of Study Patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age, y</th>
<th>Sex, M/F</th>
<th>Surgical status</th>
<th>Baseline number of polyps</th>
<th>Baseline size of the largest polyp, mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>49</td>
<td>F</td>
<td>IAP (15)</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>21</td>
<td>M</td>
<td>IRA 15</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>51</td>
<td>F</td>
<td>IRA 11</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>54</td>
<td>M</td>
<td>IRA 5</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>22</td>
<td>M</td>
<td>IRA 15</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

NOTE. Parentheses indicate ileal polyps. IAP, total proctocolectomy with ileoanal pouch; IRA, colectomy with ileorectal anastomosis.
not noted in any patient with curcumin and quercetin treatment. The compliance with scheduled drug doses by pill count was 92% (excluding the 3- to 6-month period for patient 1).

Discussion

In this study combination therapy with curcumin and quercetin appeared effective in reducing the number and size of adenomatous polyps in both the retained rectum and ileoanal pouch of patients with FAP with prior colectomy. Evidence of ileal adenoma regression is of clinical importance because recent reports highlight a risk for adenoma and adenocarcinoma development in the ileal pouch. Of note, patient 1 developed an increase in polyp number between 3 and 6 months. Investigation revealed patient noncompliance with treatment dosing during this period. With re-establishment of compliance between 6 and 9 months, the polyp number again decreased. Curcumin, a food spice, is used commonly in Asian meal preparation and is considered to have an absence of side effects. Also, quercetin, a dietary-derived supplement, has a dearth of reported adverse effects, although limited experience with this agent exists. In contrast, agents previously shown to regress colorectal adenomas in FAP patients, including sulindac and cyclooxygenase-2 inhibitors, have defined toxicities. During this trial of curcumin and quercetin, study patients had virtually no adverse events and no perturbations in laboratory values.

Findings of adenoma regression in FAP patients with curcumin are consistent with the effect of this agent in animal studies of colorectal carcinogenesis. In azoxymethane-induced murine models, curcumin inhibited the incidence and multiplicity of colonic adenocarcinomas and adenomas. Inhibition of colonic neoplasia was noted in both the initiation and promotion/progression phase of colon carcinogenesis. Some similar studies have been published with quercetin. Also, in the murine model of FAP (Min mouse) curcumin significantly decreased tumor formation by 64%. Few clinical trials of curcumin or quercetin exist. Sharma et al treated 15 patients with advanced colorectal cancer refractory to standard chemotherapy with curcumin for up to 4 months and reported radiographically stable disease in 5 patients for 2–4 months of therapy.

The putative anticancer mechanisms of curcumin include up-regulation of carcinogen-detoxifying enzymes such as glutathione S-transferases, antioxidation, and suppression of the isoenzyme cyclooxygenase-2. In a phase I clinical trial, orally administered curcumin produced a 57%–62% decrease in inducible prostaglandin E2 levels as measured in blood leukocytes. Of interest, an association between adenoma regression in FAP patients and prostaglandin levels has been noted in several recent studies of colorectal mucosal prostanoids after sulindac treatment.

The potential anticarcinogenic mechanisms of quercetin are less well understood. Of interest, flavonoid compounds are able to target the function of ras gene products. Quercetin specifically inhibits p21-Ras expression in human colon cancer cell lines and in primary colorectal cancers.
Table 2. Effect of Curcumin and Quercetin on Polyp Number and Polyp Size

<table>
<thead>
<tr>
<th></th>
<th>Mean (SD)</th>
<th>Range of polyps</th>
<th>Percent reduction from baseline</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyp number</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>23.7 (18.6)</td>
<td>11–45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>7.2 (6.8)</td>
<td>2–19</td>
<td>60.4</td>
<td>.043</td>
</tr>
<tr>
<td>Polyp size (mm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>5.3 (2.3)</td>
<td>4–8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>2.7 (.9)</td>
<td>2–4</td>
<td>50.9</td>
<td>.039</td>
</tr>
</tbody>
</table>

\*P values determined by Wilcoxon signed-rank test.

In summary, the potential use of curcumin and quercetin as chemopreventive agents against colorectal neoplasia is supported by animal studies and this human observational data. However, these findings need validation in a randomized, double-blind, placebo-controlled trial.

References


Address requests for reprints to: Francis M. Giardiello, MD, Johns Hopkins Hospital, 1830 East Monument Street, Baltimore, Maryland 21205. Fax: (410) 614-8337.

Supported in part by the John G. Rangos, Sr. Charitable Foundation, the Clayton Fund, and National Institutes of Health grants K07 CA092445, CA 53801, and P50 CA 62924-10. The drug for this trial was provided by the manufacturer, Farr Laboratories. Daniel A. Shoskes is a Consultant for Farr Laboratories, which made the supplement used in the study.

The authors thank Linda Welch for technical support.